PubMed Health⌕ Search

Biomedical subjects

J L Currie

Publications and source records attributed to J L Currie.

At least 55 records · Page 3Linked to original sources
PubMed1988

Epidemiology of adenocarcinoma of the cervix.

Three hundred thirty-three patients who presented with cervical carcinoma from November 1980 through June 1985 were compared for potential factors associated with histology. Sixteen percent of all patients presenting with cervical carcinoma during this 5-year period had an adenocarcinomatous histology. Emphasis was placed on demographic and socioeconomic factors. The histologic distribution was the following: epidermoid carcinoma 279, adenocarcinoma 28, and adenoepidermoid carcinoma 26. The latter two histologies were not different for any factors and therefore combined for statistical comparison with epidermoid carcinoma. When epidermoid (E) carcinoma of the cervix was compared with the histologies having an adenocarcinomatous component (A), the following demographic and socioeconomic factors were statistically, different (P less than 0.05): Unemployment (E 69% vs. A 46%) P less than 0.002; Income less than $6000/yr (E 48% vs. A 26%) P less than 0.005; Less than a 12th-grade education (E 85% vs. A 72%) P less than 0.05; Smokers (E 67% vs. A 40%) P less than 0.001; First coital experience less than 18 years (E 58% vs. A 39%) P less than 0.05. Age, parity, and number of sexual partners were not significantly different between the epidermoid and adenocarcinoma groups. The number of patients with stages II, III, and IV was too small to provide a meaningful statistical comparison of survival for the two histologies. Our data suggest that epidermoid and adenocarcinoma of the cervix may represent diseases with distinct populations at risk.

Adenocarcinoma↗
PubMed1988

Ovarian carcinoma and paraneoplastic cerebellar degeneration.

A case of paraneoplastic cerebellar degeneration complicating ovarian cancer is presented. This rare disorder is characterized by vertigo, nystagmus, diplopia, and ataxia. Neurologic sequelae are progressive, ultimately culminating in complete incapacitation and death. Symptoms of paraneoplastic cerebellar degeneration precede the diagnosis of malignancy in the majority of cases. Marked elevation in the anti-Purkinje cell antibody titer together with immunofluorescent staining techniques suggest that an autoimmune mechanism plays a role in the etiology of this disorder.

Aged↗
PubMed1987

Cellular DNA content and CA-125 antigen expression in ovarian carcinomas.

Tumor tissue specimens obtained at the time of disease diagnosis from patients with ovarian carcinoma were analyzed for cellular DNA content and CA-125 antigen expression. The presence or absence of aneuploidy did not influence the expression of the CA-125 antigen. In addition, both intra- and interlesional heterogeneity of cellular DNA content and CA-125 antigen expression were noted.

Aneuploidy↗
PubMed1987

DNA content in cervical neoplasia and its relationship to prognosis.

Aneuploidy is commonly associated with malignancy and certain premalignant conditions. Recent studies have demonstrated an association between prognosis and the presence of aneuploidy. In this study, flow cytometry was used to determine the deoxyribonucleic acid (DNA) content of tissues with cervical intraepithelial neoplasia or invasive cervical carcinoma. Of 41 evaluable patients with cervical intraepithelial neoplasia, aneuploidy was demonstrated in the specimens of three of ten patients with cervical intraepithelial neoplasia II and six of 13 with cervical intraepithelial neoplasia III. No specimens with cervical intraepithelial neoplasia I, with condylomata, or without pathologic diagnosis contained aneuploid populations. Of the 22 evaluable specimens with invasive cervical carcinoma, 13 contained aneuploid populations. In stage I cervical lesions, aneuploidy appeared to be a poor prognostic factor with an overall survival of two of five patients with aneuploid tumors versus five of five patients with diploid tumors.

Aneuploidy↗
PubMed1986

1000 cGy single dose palliation for advanced carcinoma of the cervix or endometrium.

Between January 1980 and the present, 42 patients with symptomatic, incurable gynecologic malignancies were treated at the University of North Carolina with 1000 cGy in a single fraction to the pelvis, repeated once or twice at monthly intervals as necessary. Of patients with adequate follow-up, total cessation of bleeding was seen in 18 of 30 (60%), complete pain relief in 2/9 (22%), and complete tumor eradication in 7/28 (25%). These palliative benefits were permanent in approximately half of the patients. Five serious treatment complications have been documented, four occurred more than 10 months after treatment. We conclude that 1000 cGy single-fraction whole pelvis treatment can be an effective means of palliating advanced gynecologic cancer provided the patient has a life expectancy of less than 1 year. Patients with a longer life expectancy are at risk for both recurrence of symptoms and for treatment related complications.

Adult↗
PubMed1985

Endometriosis with massive ascites.

One case of extensive endometriosis with ascites in a young nulliparous woman is reported. The patient had been maintained on suppressive therapy with danazol for over two years, demonstrating the feasibility of conservative management in this extremely rare form of endometriosis. However, long-term efficacy and potential for fertility remain to be determined.

Adult↗
PubMed1984

Percutaneous nephrostomy in gynecologic oncology.

Percutaneous nephrostomy is a useful method of supravesical diversion when ureteral obstruction occurs at initial diagnosis of gynecologic cancer or recurrence of disease. Although survival is prolonged, the attendant quality of life would indicate that percutaneous nephrostomy should be performed only in those cases in which there is a reasonable chance for palliation or a hope for cure or when temporization is needed to define adequately the etiology of ureteral obstruction following therapy.

Female↗
PubMed1984

Single-fraction palliative pelvic radiation therapy in gynecologic oncology: 1,000 rads.

The management of the patient with advanced gynecologic malignancies presents multiple problems for the gynecologic and radiation oncologists involved in their care. When palliative management only is indicated, conventional treatment protocols occupy a significant portion of the patient's remaining life span, often times with associated morbidity. Single-fraction external radiation therapy, consisting of 1,000 rads to the whole pelvis, was used in 30 patients with advanced gynecologic malignancies to palliate locally advanced pelvic disease. Alleviation of symptoms and maintenance of a reasonable quality of life were obtained in all patients. No untoward acute side effects were observed. Thirteen patients are alive from 2 to 19 months after treatment, with a mean overall survival after treatment of 8.4 months. It is concluded that this regimen should be considered as the palliative therapy of choice for certain patients with advanced gynecologic malignancies.

Adult↗
PubMed1984

Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma. A Gynecologic Oncology Group study.

In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable.

Adult↗
PubMed1984

Steroid receptors in endolymphatic stromal myosis.

Endolymphatic stromal myosis is a neoplasm derived from the endometrial stromal cell. As such it should respond to hormonal manipulation. Reported are positive estrogen and progesterone cytosol receptors in three cases of endolymphatic stromal myosis with disease regression following progestational therapy. Estrogen and progesterone receptor studies are recommended in all cases of endolymphatic stromal myosis. When positive, progestational therapy is appropriate.

Adult↗
PubMed1983

Intracavitary Corynebacterium parvum for treatment of malignant effusions.

Intracavitary instillation of Corynebacterium parvum was used to treat recurrent malignant effusions in 15 patients. Eleven patients were treated for ascites, and four patients were treated for pleural effusion. Six patients (40%) had good response with no recurrence of effusions up to 3 months after treatment. Three patients responded but died before criteria for complete response could be fulfilled. Six patients were judged to have poor response, either because of death from tumor burden before evaluation could be made or because of recurrent effusions. There were no serious side effects directly attributed to intracavitary C. parvum therapy. Analysis of the results in this preliminary study suggests that patients who have had prior good response to chemotherapy, whose performance scale is adequate, whose tumor burden is not preterminal, and who have been previously treated with immunotherapy may be excellent candidates for definitive treatment of malignant effusions with intracavitary C. parvum.

Adult↗
PubMed1983

Observations on the intraperitoneal distribution of chromic phosphate (32P) suspension for intraperitoneal therapy.

Seven patients received intraperitoneal chromic phosphate (32P) suspension in a 3-ml bolus with a saline flush, and another ten patients were given the suspension in a 500-ml infusion of normal saline. During the first six hours after administration, most 32P activity redistributed to the gravity-dependent portion of the peritoneal cavity. From 24 hours up to seven weeks after administration, activity distributions were fixed. Dispersions were heterogeneous in every patient, but the most marked examples of localized activity occurred in patients who had received bolus injections. We concluded that large-volume infusions and frequent changes in patient position for several hours following the infusion, contribute to improved dispersion of 32P suspension.

Chromium↗
PubMed1982

Chemotherapy with the modified Bagshawe protocol for poor prognosis metastatic trophoblastic disease.

The Southeastern Regional trophoblastic Disease Center has treated 126 patients with metastatic gestational trophoblastic disease from 1966 through 1979. Sixty-three cases were categorized as having a poor prognosis on the basis of criteria published previously. Since 1976, 18 patients have been treated with a modification of Bagshawe's multiagent chemotherapy protocol. Ten of 18 patients (56%) have achieved sustained remission. Seventy-eight percent of these patients encountered serious myelosuppression (white blood count 1000 cells or fewer) and 39% suffered severe thrombocytopenia (platelet count 50,000 or fewer). There were no deaths related to drug toxicity. The courses of therapy and complications of modified Bagshawe chemotherapy are reviewed.

Antineoplastic Agents↗
PubMed1980

The role of operation in the current therapy of gestational trophoblastic disease.

Results of therapy of 257 patients with gestational trophoblastic disease (GTN), treated at one institution and by the same group of physicians (1966 to 1978), are presented. An overall remission rate of 92% was achieved: nonmetastatic disease, 139/139 (100%); "good" prognosis metastatic GTN, 55/55 (100%), "poor" metastatic GTN, 42/63 (66%). Chemotherapy, single- or multi-agent, was the primary treatment modality but selected patients were also treated with operation and/or x-ray therapy. Surgical therapy (hysterectomy), performed coincident with the institution of systemic chemotherapy, was shown to significantly reduce the duration of hospitalization and the amount of chemotherapy used to achieve remission, regardless of whether or not metastases were present. Delayed surgical excision of chemotherapy-resistant foci of GTN was of benefit, though less effective than initial operation. Surgical intervention for other diseases or for complications of GTN or its treatment was quite useful to stabilize patients and allow successful chemotherapy to be completed. There were no problems attributable to chemotherapy when wound healing or other postoperative complications were considered.

Antineoplastic Agents↗
PubMed1978

Clinical experience with the copper 7 intrauterine device.

This paper reports further observations on our previous study of 203 Copper 7 intrauterine insertions performed in 199 women. There have now been accumulated 3799 woman-months of use. At least a 2-year period of observation has been attained from first insertion until these data were analyzed. The Copper 7 intrauterine device (IUD) continues to be an acceptable contraceptive method with regard to effectiveness, continuation, and lack of serious complications. Those patients who elected to have their copper 7 IUDs removed for planned pregnancy were also analyzed with regard to fertility capacity. Possible complications with the need to change the copper 7 IUD and risk of prolonged use were not verified. There was a decrease in contraceptive effectiveness after 12 more months' use.

Female↗